Study of atazanavir-induced hyperbilirubinemia among HIV patients on second-line anti-retroviral therapy

Study of atazanavir-induced hyperbilirubinemia among HIV patients on second-line anti-retroviral therapy

Introduction: Ritonavir-boosted atazanavir (ATV/r) is the preferred second-line protease inhibitor option for HIV patients as per the NACO guidelines. Atazanavir is a protease inhibitor with several advantages including once-daily dosing, low pill burden, and favorable effect on lipid profile compar...

Full description

Bibliographic Details
Main Authors: K Ravi, G N Devamsh, K J Umesh, B C Prashant
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2020-01-01
Series:APIK Journal of Internal Medicine
Subjects:
atazanavir
hiv patients
hyperbilirubinemia
Online Access:http://www.ajim.in/article.asp?issn=2666-1802;year=2020;volume=8;issue=1;spage=15;epage=18;aulast=Ravi

Internet

http://www.ajim.in/article.asp?issn=2666-1802;year=2020;volume=8;issue=1;spage=15;epage=18;aulast=Ravi

Similar Items